女性生育力保存:25年进展、适应证扩展与未来展望
本综述回顾了自20世纪90年代末以来生育力保存领域的进展,检索PubMed、Embase和Cochrane Library从建库至2025年5月的英文文献。文章总结了卵母细胞冷冻成为标准技术、随机启动卵巢刺激方案的验证、卵巢组织冷冻的改进,以及GnRH类似物未能改善活产率等证据,并展望了体外卵泡生长和配子发生等未来方向。
要点
- 卵母细胞冷冻在玻璃化技术普及后已被定义为生育力保存的标准技术。
- 随机启动卵巢刺激方案的适用性、成功性和安全性已在包括Meta分析在内的多项研究中得到证实。
- GnRH类似物联合化疗虽在部分人群中降低早发性卵巢功能不全发生率,但未证明改善活产率。
核心结论
- 生育力保存技术的演变对临床实践具有深远影响,不仅影响面临生育力受损治疗或状况的个体,也可能推迟生殖衰老。
- 体外原始卵泡生长和配子发生的出现可能进一步革新生殖医学和生育力保存的格局。
研究设计与样本
- 本综述检索了PubMed、Embase和Cochrane Library数据库中从建库至2025年5月的英文同行评议文献,关键词包括生育力保存、卵巢衰老、化疗、放疗、胚胎冷冻、卵母细胞冷冻、卵巢组织冷冻和体外卵泡生长。
主要发现
- 胚胎冷冻在辅助生殖技术领域早已成功开展;随着玻璃化技术的出现和广泛使用,卵母细胞冷冻去除了实验性标签并被定义为生育力保存的标准技术。
- 随机启动卵巢刺激方案的适用性、成功性和安全性已在包括Meta分析在内的许多研究中得到证实。
- 通过机器人手术、使用新生血管化细胞外基质和辅助药物治疗,卵巢组织冷冻结局的改善已有报道。
- GnRH类似物联合化疗已作为避免生育力保存需求的一种方式进行了试验;尽管在某些以此方式治疗的患者人群中报告早发性卵巢功能不全发生率较低,但未证明活产率改善。
- 动物研究已报告体外卵泡生长成功,人类卵巢组织方面也正在取得进展。
临床怎么用
- 由于随机启动卵巢刺激方案和抗雌激素药物与卵巢刺激药物联合使用的引入,加上卵母细胞冷冻成功率的提高、卵巢组织冷冻的改进和移植技术的精炼,女性现在可以通过个体化方法受益于各种生育力保存选项。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There has been an unprecedented progress in the field of fertility preservation (FP) beginning in the late 1990s. Specifically, technological innovations, refinements in the protocols, and a deeper understanding of reproductive physiology have collectively contributed the increased success and utilization of FP methods. OBJECTIVE AND RATIONALE: The objectives of this review are: (i) to identify the most recent and significant advances in FP, and (ii) based on evidence, to provide a comprehensive and up-to-date source of contemporary FP management approaches to guide clinicians in critical decision-making. In addition to cancer treatments, the indications for FP have expanded to include various systemic conditions such as haematological, metabolic, genetic, and immunological disorders, as well as gonadal surgery and a wish to delay childbearing. Due to the introduction of random start ovarian stimulation protocols and use of anti-oestrogen agents along with ovarian stimulation drugs, coupled with increased success with oocyte cryopreservation, improvements in ovarian tissue cryopreservation and refinements of transplantation techniques, women can now benefit from various FP options through an individualized approach. SEARCH METHODS: We searched for peer-reviewed articles in PubMed, Embase, and Cochrane Library databases containing the key words: FP, ovarian ageing, chemotherapy, radiotherapy, embryo cryopreservation, oocyte cryopreservation, ovarian tissue cryopreservation, and in vitro follicle growth, in the English-language literature from inception to May 2025. OUTCOMES: Cryopreservation of embryos have long been performed successfully in the field of ART. With the advent and widespread of use vitrification, the experimental tag was removed and oocyte cryopreservation was defined as a standard technique of FP. The applicability, success, and safety of random start ovarian stimulation protocols have been demonstrated in many studies including meta-analyses. Improvements in ovarian tissue cryopreservation outcomes have been reported with robotic surgery, use of neovascularizing extracellular matrix, and adjuvant pharmacotherapy. The use of GnRH analogues along with chemotherapy has been trialled as a way of avoiding the need for FP. Although the rate of premature ovarian insufficiency was reported to be lower in some patient populations treated this way, no improvements in live birth rates have been demonstrated. Among the emerging and future options are the use of ovarian tissue freezing and pharmacological approaches to delay menopause and reproductive ageing, non-suppressive gonadoprotective pharmacotherapy, in vitro gametogenesis and in vitro purging of cancer cells from ovarian tissue for cryopreservation. Animal studies have reported success with in vitro follicle growth, and progress is being made with human ovarian tissue. WIDER IMPLICATIONS: The evolution of FP techniques has profound implications for clinical practice, not only for individuals facing fertility-compromising treatments or conditions, but also for the potential deferral of reproductive ageing. The advent of in vitro primordial follicle growth and gametogenesis may further revolutionize the landscape of reproductive medicine and FP. REGISTRATION NUMBER: N/A.
引用
- Sonmezer M, Sacinti KG, Oktay KH, et al. Female fertility preservation: 25 years of progress, expanding indications and future prospects. Hum Reprod Update. 2026. PMID: 41206517. doi:10.1093/humupd/dmaf026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。